A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

NCT04975893 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infection

Interventions

BIOLOGICAL: mRNA-1647
OTHER: mRNA-1647

Sponsor

ModernaTX, Inc.